To the Editor:

I have read with great interest the article published by Kathirvel et al[@bib1] "Tenecteplase versus streptokinase thrombolytic therapy in patients with mitral prosthetic valve thrombosis." The authors conducted a study in which they compared two modalities of thrombolytic therapy (TT) (streptokinase vs tenecteplase) in patients with mechanical prosthetic valve thrombosis (PVT) in mitral position.

They reported a favorable outcome with tenecteplase as compared with streptokinase and a complete therapeutic success rate of more than 75% in these patients.

Despite the limitations of the study, mainly because of the low number of patients included, it recognizes TT as the first-choice therapeutic option in PVT in developing countries such as India.

I would like to emphasize the importance of TT as an initial therapeutic option and highlight that this treatment is not just for developing countries; rather, the emerging evidence supports it to be a universal intervention in patients with PVT.

For several years, we have recommended TT as the first therapeutic indication in PVT.[@bib2]

Our meta-analysis provides evidence that suggests a primary role for thrombolysis in patients with PVT, and we have concluded that surgery has not been proved superior to thrombolysis.[@bib3]

In the Ultra-slow PROMETEE trial,[@bib4] the authors reported 90% of therapeutic success rate. The overall complication rate was 6.7% (3.3% nonfatal major, 2.5% minor, and 0.8% death). The authors concluded that the TT was efficient with low mortality rates and low risk of nonfatal complications.

Regarding the therapeutic intervention in PVT, there has been a remarkable change in the latest update of the American Heart Association/American College of Cardiology guidelines for the management of valvular heart diseases.[@bib5] It matches the indication level and emphasizes the need for urgent initial treatment with either slow-infusion low-dose fibrinolytic therapy or emergency surgery in patients with a left-sided mechanical PVT presenting with symptoms of valve obstruction (recommendation class I[-]{.ul}B). In addition, this last update adds a group of clinical factors to be considered when taking therapeutic decisions, including the choice of the patient and the institutional capacity.
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